---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-25-000004"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:52:46.781729+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS reports FY2024 net loss $30.9M; Phase 3 REGAL trial interim analysis positive

## Summary
- Net loss $30.9M ($0.50/share) vs $37.3M ($1.34) in FY2023; R&D expenses down to $19.1M.
- Cash $13.9M at Dec 31, 2024; raised $25M in January 2025 registered direct offering.
- Positive interim analysis for Phase 3 REGAL trial (GPS in AML); final analysis expected upon 80 events in 2025.
- Phase 2 SLS009 in r/r AML: 56% ORR in AML-MRC cohorts; median OS >7.7 months vs historic ~2.5 months.
- Received multiple regulatory designations: three FDA RPDD, one Fast Track, two EMA ODD.

## SEC filing metadata
- accession: 0001390478-25-000004
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/0001390478-25-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-25-000004
- JSON: https://secwatch.observer/filing/0001390478-25-000004.json
- Plain text: https://secwatch.observer/filing/0001390478-25-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.